📊 CLGN Key Takeaways
Investment Thesis
Insufficient financial data available for fundamental analysis. SEC EDGAR filings show no disclosed revenue, profitability metrics, or balance sheet details for the latest reporting period. Cannot assess financial health, operational performance, or growth trajectory without core financial statements.
CLGN Strengths
- Listed on Nasdaq exchange indicating some regulatory compliance
- Operating in orthopedic/surgical appliances sector with potential market applications
- SEC registered company with public disclosure requirements
CLGN Risks
- Complete absence of revenue and profitability data suggests pre-commercial or distressed financial condition
- No balance sheet metrics available to assess liquidity or solvency
- No cash flow data available; unable to evaluate operational sustainability or capital requirements
- Zero insider trading activity in last 90 days suggests limited management confidence or activity
- Extremely limited data quality with only 1 metric available out of comprehensive suite
Key Metrics to Watch
- Revenue recognition and gross margin upon commercialization
- Cash burn rate and liquidity position relative to runway
- Clinical trial progress and regulatory milestones for product portfolio
CLGN Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CLGN Profitability Ratios
CLGN vs Default Sector
How CollPlant Biotechnologies Ltd compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CLGN Balance Sheet & Liquidity
CLGN Growth Metrics (YoY)
CLGN SEC Filings
Access official SEC EDGAR filings for CollPlant Biotechnologies Ltd (CIK: 0001631487)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLGN
What is the AI rating for CLGN?
CollPlant Biotechnologies Ltd (CLGN) has an AI rating of HOLD with 15% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLGN's key strengths?
Listed on Nasdaq exchange indicating some regulatory compliance. Operating in orthopedic/surgical appliances sector with potential market applications.
What are the risks of investing in CLGN?
Complete absence of revenue and profitability data suggests pre-commercial or distressed financial condition. No balance sheet metrics available to assess liquidity or solvency.
What is CLGN's revenue and growth?
CollPlant Biotechnologies Ltd reported revenue of N/A.
Does CLGN pay dividends?
CollPlant Biotechnologies Ltd does not currently pay dividends.
Where can I find CLGN SEC filings?
Official SEC filings for CollPlant Biotechnologies Ltd (CIK: 0001631487) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLGN's EPS?
CollPlant Biotechnologies Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.